TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum plasma concentration (Cmax) of macitentan and tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from 0 to time t [AUC(0-t)] of macitentan and tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve to infinity [AUC(0-inf)] of macitentan and tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody seropositivity of 1 dose compared with 2 or 3 doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody geometric mean titre (GMT) of 1 dose compared with historical cohorts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody seropositivity of 1 dose compared with 2 doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose of sorafenib tosylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary iodine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants That Died Within 28 Days Post Injury
Endpoint domain: Mortality/survival
Primary endpoint: Intensity reduction of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score of Chinese Perceived Stress Scale (CPSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in score of Medical Outcomes Study Questionnaire Short Form 36 Health Survey (36-Item Short Form Survey)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 6-minute walk test (6 MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance over bioavailability (CL/F) of pitavastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal clearance (CLr) of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance (CLr) of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal clearance (CLr) of adefovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: increase in lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ECG Voltage spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Posterior keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Homeostasis Model Assessment (HOMA) for Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success of Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of burning sensation in patients with BMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of leaking water drops from the nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of air flow through the nose during speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to rice bran consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Durable Complete Response Proportion (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength and Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in caregiver self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Score Difference in Symptoms of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score Difference in Symptoms of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score Difference in Symptoms of Post-Traumatic Stress Disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Protocol-defined Wheezing Illness (PDWI) Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: blood oxygenation level dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: structural MRI measures (grey and white matter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Response to Stress Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Shear wave elastography score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients developing grade 2 or above rash
Endpoint domain: Adverse events/effects
Primary endpoint: Change in inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Log-transformed Circulating CRP Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Drug Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in High Risk Sexual Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HIV Testing behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the number of gas incontinence and soiling episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's Subjective Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in BASDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of angioedema events
Endpoint domain: Adverse events/effects
Primary endpoint: Time of angioedema events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of angioedema events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma lixisenatide concentration curve (LIX-AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lixisenatide maximum plasma/serum peak concentration (LIX-Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experience Study-drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Attendance at a VA Appointment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time until emergency stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in FEV1 (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Local field potential (LFP) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oral mucosal severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject's Rating of Medication Helpfulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance in Psychomotor Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroblast Growth Factor 23 (FGF-23) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity (T-cell response in peripheral blood)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative Recovery of [14C]-Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Technical success rate for elective interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of unprotected sexual acts with nonspousal partners
Endpoint domain: Adverse events/effects
Primary endpoint: Overall observed incidence of sexually transmitted diseases (STDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and tolerability of AMD3100
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Left Ventricular Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of symptomatic FTD patients or presymptomatic subjects at risk of genetic FTD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in neuroinflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in structural MR metrics of brain tissue damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of bacterial pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Biopsy Proven Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: malaria parasitaemia during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cardiac Output using ergospirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vascular Resistance using ergospirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Oxymetazoline plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruising Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of BPD at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of mortality at 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Presence of FACBC radiotracer in breast carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acceptability of clinic process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in VPT following trabeculectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VPT following ocriplasmin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse to heavy drinking
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with abnormal ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC
Endpoint domain: Physiological/clinical
Primary endpoint: Maximum Testosterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Dihydrotestosterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Estradiol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Excess retinal thickness on OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at first smoking cessation session
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Eating Disorder Risk score (EDRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ineffectiveness (IC) of the EDI-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coverage of EPI vaccines and health interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Molecular markers of resistance to Sulfaxodine-pyrimethamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Endometrial expression of implantation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total number of isolated CTCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of newborns requiring pharmacological treatment for neonatal abstinence syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average length of stay on site of the catheter
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: MS quantitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance inhaler adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Transmission of infection to contacts
Endpoint domain: Adverse events/effects
Primary endpoint: Vertical Jump test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of ultrasound morphometry in predicting groin lymph node status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Negative predictive value (NPV) of ultrasound morphometry in predicting groin lymph node status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive predictive value (PPV) of ultrasound morphometry in predicting groin lymph node status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of fine needle aspiration in predicting groin lymph node status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Negative predictive value (NPV) of fine needle aspiration in predicting groin lymph node status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disease severity in advanced stages of dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One month gaps in effective contraceptive use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Presence of Dyssynergia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Balloon Expulsion Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Complete Spontaneous Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global Bowel Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Level of childbirth related fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Live/Dead Myeloma Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Exercise intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methacholine Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain sensation during mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Oxygen Partial Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CO2 Partial Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical performance measured by VO2-max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration of pancreatic islet function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Overall Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Abdominal Pain Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Stool Frequency Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pittsburgh Sleep scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Insomnia sleep scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: SF 15 pain descriptor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of CDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of intraoperative cholangiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Burnout level as measured by Maslach's burnout inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUCτ,ss of atorvastatin and free ezetimibe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax,ss of atorvastatin and free ezetimibe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Movement Assessment Battery for Children 2 (MABC2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental Coordination Disorder Questionnaire (DCDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Trail Making B (time in seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emulsification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete eradication of diminutive polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Spleen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Daytime Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good outcome of patients treated with OMT
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: p38 MAPK Activity in Macrophages or PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: dosage of CD26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dosage of copeptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dosage of troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dosage of IMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dosage of adenosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of colony forming units of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Identification rate of microorganisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Severity Score of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of SARS-CoV2 ELISA method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory evolution at 24 months corrected age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neurodevelopmental evolution at 24 months corrected age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Growth evolution at 24 months corrected age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracellular concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With Positive T Wave Studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Change From Baseline Value in Clinical Laboratory Hematology Test Results to Worst Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Change From Baseline Value in Clinical Laboratory Chemistry Test Results to Worst Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in mean number of nocturnal voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Successful H. pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Surviving at One and Four Years After Liver Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Change in Short-term Virologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Output Within and Outside 20% of Baseline Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes